Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual Immunotherapy in Children with Allergic Rhinitis
NCT04851860Phase 3Unknown
- Sponsor
- Zagazig University
- Start
- Apr 2021
- Primary completion
- Oct 2021
- Modality
- Allergy Immunotherapy
01
Overview
Phase 3, open-label trial of house dust mite allergen extract in allergic rhinitis (AR), sponsored by Zagazig University. Primary endpoint: Platelet Factor 4 at 26 weeks. Status: unknown.
02
Drugs
house dust mite allergen extract
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT04851860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04851860.